Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of ICD (Box 1) (Erkes et al., 2020; Wang et al., 2020a)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Erkes et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 3×
“We confirmed the ability of etoposide and also tested doxorubicin, a known chemotherapeutic inducer of pyroptosis, for ability to cause GSDME cleavage in CRT cell lines (31,32,34).”
BackgroundSelf-citationToll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundClassification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
Background
Cited by
Items 101–200 of 520
Tong, W., Guo, J., & Yang, C. (2020) · Bioscience Reports · doi:10.1042/bsr20200259 · Cited by 52
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
“It also resulted in a boost in the expression of granzyme B, perforins, IFN-γ, and TNF-α in TILs, as well as an increase in the phagocytosis of tumor cells by tumor-associated macrophages in a melanoma xenograft model treated with serine/threonine-protein kinase B-raf (BRAF) and mitogen-activated protein kinase kinase…”
BackgroundYang, H., Zhang, Z., Li, J., Wang, K., Zhu, W., & Zeng, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111825 · Cited by 50
Programmed cell death in tumor immunity: mechanistic insights and clinical implications
Wang, M., Yu, F., Zhang, Y., & Li, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1309635 · Cited by 52
“Pyroptotic cancer cell-derived DAMPs activated DCs to promote T cell expansion, which led to tumor regression.”
BackgroundInfluentialSOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects
Rosenbaum, S. R., Tiago, M., Caksa, S., Capparelli, C., Purwin, T. J., Kumar, G., Glasheen, M. Q., Pomante, D., Kotas, D., Chervoneva, I., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110085 · Cited by 49
Self-citationEnhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance
Yang, Z., Wang, Y., Liu, S., Deng, W., Lomeli, S. H., Moriceau, G., Wohlschlegel, J. A., Piva, M., & Lo, R. S. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1463 · Cited by 48
“The ways in which syngeneic murine melanoma, in response to MAPKi therapy, undergoes “immunogenic” cell death (25) and evades antitumor immunity (this study) directly regulate the durability of MAPKi responses, as do tumor mutational burden (this study and our prior study of NrasMUT melanoma; ref.”
Cancer-associated pyroptosis: A new license to kill tumor
Kong, Q., & Zhang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1082165 · Cited by 48
“tumor immunity? It has been shown that CAP is associated with more active tumor-infiltrating immune cells such as dendritic cells, CD4 and CD8 T cells and NK cells (54, 62), which lead to the control or rejection of the implanted tumors.”
BackgroundInfluentialElevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
El-Kenawi, A., Berglund, A., Estrella, V. C., Zhang, Y., Liu, M., Putney, R. M., Yoder, S., Johnson, J., Brown, J. S., & Gatenby, R. A. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1002 · Cited by 47
“These treatments induced cell death with balloon-like bubbles reminiscent of pyroptotic cell morphology (23, 24).”
InfluentialXuzhang, W., Lü, T., Jin, W., Yu, Y., Li, Z., Shen, L., Niu, X., Ai, X., Xia, L., & Lü, S. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.89080 · Cited by 46
Emerging insights on the role of gasdermins in infection and inflammatory diseases
Tang, L., Lu, C., Zheng, G., & Burgering, B. M. T. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1186 · Cited by 46
“Additionally, Erkes and colleagues found that combined BRAF inhibitor and MEK inhibitor treatment causes GSDMEmediated pyroptosis in BRAF V600E/K -mutant melanoma via active caspase-3, ultimately resulting in HMGB-1 release to activate antitumor T-cell responses.(39) Collectively, these studies define a new functional…”
BackgroundHow far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)
Tabbò, F., Pisano, C., Mazières, J., Mezquita, L., Nadal, E., Planchard, D., Pradines, A., Santamaría, D., Swalduz, A., Ambrogio, C., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102335 · Cited by 47
Diselenide‐Based Dual‐Responsive Prodrug as Pyroptosis Inducer Potentiates Cancer Immunotherapy
Wan, S., Ye, M., Yang, Q., Zhang, T., Zhang, M., Ma, X., Xu, J., Wang, S., Wu, Z., Yang, L., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202135 · Cited by 46
Zhu, W., Ye, Z., Chen, L., Liang, H., & Cai, Q. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108268 · Cited by 45
Wang, S., Liu, Y., Xiao, H., Chen, Z., Yang, X., Yin, J., Li, Y., Yuan, C., Yan, S., Chen, G., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06301-1 · Cited by 45
“Other data used during the study were available from the corresponding author on reasonable request.”
MethodMechanism and role of regulated cell death in tumor immunity and immunotherapy
Hu, J., Li, Y., Lian, B., Mao, Y., & Zhao, L. (2025) · 癌症:英文版 · doi:10.1002/cac2.70064 · Cited by 45
Conrad, M., Strasser, A., Jost, P. J., Yuan, J., Shao, F., Vandenabeele, P., & Wahida, A. (2026) · Cell · doi:10.1016/j.cell.2026.03.024 · Cited by 46
Caforio, M., de Billy, E., Angelis, B. D., Iacovelli, S., Quintarelli, C., Paganelli, V., & Folgiero, V. (2021) · Cancers · doi:10.3390/cancers13164040 · Cited by 44
Dilenko, H., Tomankova, K. B., Válková, L., Hošíková, B., Kolaříková, M., Malina, L., Bajgar, R., & Kolářová, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s461300 · Cited by 43
What role does pyroptosis play in cancer?
Huang, C. L., Li, J., & Zhang, C. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101587 · Cited by 44
“However, GSDME deficiency inhibits anti-tumor immunity [149,150].”
Huang, S., Gong, S., Zhao, Y., Ye, M., Li, J., He, Q., Qiao, H., Tan, X.-R., Wang, J.-Y., Liang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49675-2 · Cited by 42
“Since GSDME-mediated pyroptosis promotes the release of DAMPs (e.g., HMGB1 and calreticulin) and then activates DCs and enhances CD8 + T-cell-mediated antitumour immunity 15 , we further explored whether PJA1 can regulate antitumour immunity.”
BackgroundCaspase-Independent Regulated Necrosis Pathways as Potential Targets in Cancer Management
Lou, J., Zhou, Y., Feng, Z., Ma, M., Yao, Y., Wang, Y., Deng, Y., & Wu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.616952 · Cited by 42
Programmed cell death network in cancer drug resistance: A framework for therapeutic intervention
Guo, D., Guo, Y., Zhu, C., Liao, Y., Lin, Z., Zhang, H., Zhang, W., & Zou, Z. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101387 · Cited by 41
Role of HMGB1 in Cutaneous Melanoma: State of the Art
Pomi, F. L., Borgia, F., Custurone, P., Vaccaro, M., Pioggia, G., & Gangemi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169327 · Cited by 41
“These data implicate that BRAFi + MEKi-induced pyroptosis in antitumor immune responses is a valid therapeutic strategy and highlights possible new therapeutic approaches for resistant melanoma [43].”
BackgroundPhase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF -mutated Urothelial Carcinoma
Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0893 · Cited by 41
“In addition to apoptotic cell death, melanoma cells treated with BRAF inhibitors can undergo pyroptosis in which pores release inflammatory cytokines activating dendritic cells (4).”
BackgroundImproved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis
Mei, Z., Xingyu, C., Chen, Y., Xiaodong, S., Lv, S., & Wei, S. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01792-3 · Cited by 40
“Small molecule inhibitors [12] or chemotherapy drugs [13], promoted caspase3 activated to induced cleaved of GSDME, GSDME directly transformed non-inflammatory cell apoptosis into pyroptosis through the formation of pore permeable plasma membrane.”
BackgroundAndrogen receptor is a determinant of melanoma targeted drug resistance
Samarkina, A., Youssef, M. K., Ostano, P., Ghosh, S., Ma, M., Tassone, B., Proust, T., Chiorino, G., Levesque, M. P., Goruppi, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42239-w · Cited by 40
“The ef fi cacy of BRAF inhibitors depends on triggering a cancer cell death program associated with an impact on the tumor immune microenvironment 42 .”
BackgroundBI 2536 induces gasdermin E-dependent pyroptosis in ovarian cancer
Huo, J., Shen, Y., Zhang, Y., & Shen, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.963928 · Cited by 40
“Several promising small molecules and nanomaterials have been reported in different cancers, such as non-small cell lung carcinoma (24–26), colorectal cancer (12, 27–29), hepatocellular carcinoma (30–32), breast cancer (33–36), melanoma (11, 16, 34), and glioblastoma (37–40).”
BackgroundTargeting pyroptosis to treat ischemic stroke: From molecular pathways to treatment strategy
Li, L., Shi, C., Dong, F., Xu, G., Lei, M., & Zhang, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112168 · Cited by 40
Challenges of Regulated Cell Death: Implications for Therapy Resistance in Cancer
D’Amico, M., & Amicis, F. D. (2024) · Cells · doi:10.3390/cells13131083 · Cited by 39
“Furthermore, the combination of BRAF inhibitors and MEK inhibitors alters the tumor microenvironment by inducing pyroptosis [74].”
BackgroundHarnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 39
The future of targeted kinase inhibitors in melanoma
Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 39
“Adding MEKi to BRAFi also increases CD8+ and CD4+ TILs (Homet Moreno, Mok, Comin-Anduix, Hu-Lieskovan, & Ribas, 2016); anti-tumor responses mediated by this combination are T-cell dependent (Erkes et al., 2020).”
BackgroundSelf-citationCircular RNA and tumor microenvironment
Song, H., Liu, Q., & Liao, Q. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01301-z · Cited by 37
Biological Functions of Gasdermins in Cancer: From Molecular Mechanisms to Therapeutic Potential
Wang, M., Chen, X., & Zhang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.638710 · Cited by 39
Caspase-3/GSDME mediated pyroptosis: A potential pathway for sepsis
Jiao, C., Zhang, H., Li, H., Fu, X., Lin, Y., Cao, C., Liu, S., Liu, Y., & Li, P. A. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111022 · Cited by 36
Cell death in tumor microenvironment: an insight for exploiting novel therapeutic approaches
Wang, W., Li, T., & Wu, K. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02376-1 · Cited by 37
“GSDME expressed by the pyroptostic cell the combined treatment of BRAF and MEK inhibitors in melanoma can elevate the amount of T cells and DCs, while GSDME-de fi cient melanoma exhibited less HMGB1 release and BRAFi and MEKi resistance [185].”
Gasdermin E mediates photoreceptor damage by all-trans-retinal in the mouse retina
Cai, B., Liao, C., He, D., Chen, J., Han, J., Lu, J., Qin, K., Liang, W., Wu, X., Liu, Z., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101553 · Cited by 36
Induction of pyroptotic cell death as a potential tool for cancer treatment
Faria, S. S., Fernando, A. J., de Lima, V. C. C., Rossi, A. G., de Carvalho, J. M. A., & Magalhães, K. G. (2022) · Journal of Inflammation · doi:10.1186/s12950-022-00316-9 · Cited by 36
“Gsdme gene silencing in melanoma cells has been shown to reduce pyroptotic cell death and resulting immune infiltrate [48], thus boosting anti-cancer immunity under experimental conditions [49].”
BackgroundPyroptosis: A road to next-generation cancer immunotherapy
Fang, Y., Tang, Y., & Huang, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101782 · Cited by 37
Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy
Li, Z., Liu, Y., Fang, X., & Shu, Z. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290346 · Cited by 35
Nan, Z., Dou, Y., Chen, A., Wang, K., Sun, J., Meng, Z., Neckenig, M. R., Ai, D., Liu, S., Dong, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1100417 · Cited by 35
“Most recently, pyroptosis, an inflammatory form of programmed cell death, was shown to mediate the antitumor immune responses and the resistant mechanism of BRAF and MEK inhibitors for melanoma (14, 15).”
BackgroundPyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment
Wang, A., Wang, Y., Du, C., Yang, H., Wang, Z., Jin, C., & Hamblin, M. R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189058 · Cited by 35
Miao, Y., Quan, W., Dong, X., Gan, J., Ji, C.-F., Wang, J., & Zhang, F. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01421-1 · Cited by 34
Nanomedicine-induced programmed cell death enhances tumor immunotherapy
Lu, J., Tai, Z., Wu, J., Li, L., Zhang, T., Liu, J., Zhu, Q., & Chen, Z. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.09.018 · Cited by 34
“The Food and Drug Administration (FDA) has given the drug combination of BRAF and MEK inhibitors permission for the treatment of BRAF V600E/K mutant melanoma because it encourages GSDME cleavage and the release of HMGB-1[84].”
BackgroundLi, M., Zhong, X., & Xu, W. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2092166 · Cited by 33
“Cell pyroptosis is a type of programmed inflammation-associated cell death, which is reported to be related with the occurrence of many diseases, such as atherosclerosis [51], multiple sclerosis [52], melanoma [53], spinal cord injury [44] and asthma [3].”
BackgroundMyeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer
Li, L., Li, M., & Jia, Q. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154711 · Cited by 34
Synergistically Augmenting Cancer Immunotherapy by Physical Manipulation of Pyroptosis Induction
Zhao, C., Zheng, T., Wang, R., Lin, X., Hu, Z., Zhao, Z., Dai, Z., & Sun, D. (2024) · Phenomics · doi:10.1007/s43657-023-00140-y · Cited by 33
“Pyroptosis increases ATP levels in the cancer micro-environment, facilitating macrophage migration and dendritic cell (DCs) recruitment (Wang et al. 2013b).”
BackgroundInfluentialYang, Q., Ma, X., Xiao, Y., Zhang, T., Yang, L., Yang, S., Liang, M., Wang, S., Wu, Z., Xu, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.024 · Cited by 33
Wu, S., Wang, B., Li, H., Wang, H., Du, S., Huang, X., Fan, Y., Gao, Y., Gu, L., Huang, Q., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03013-4 · Cited by 32
RetractedTargeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Saxena, R., Welsh, C. M., & He, Y.-W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462339 · Cited by 34
Non-Canonical Programmed Cell Death in Colon Cancer
Pan, B., Zheng, B., Xing, C., & Liu, J. (2022) · Cancers · doi:10.3390/cancers14143309 · Cited by 32
“HMGB1 becomes the marker of pyroptosis [86].”
Kim, J., Kim, T., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01936-w · Cited by 31
Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential
Ryder, C. B., Kondolf, H. C., O'Keefe, M. E., Zhou, B., & Abbott, D. W. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167183 · Cited by 31
The gasdermins: a pore-forming protein family expressed in the epidermis
Slaufova, M., Karakaya, T., Filippo, M. D., Hennig, P., & Beer, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254150 · Cited by 30
Shan, Z., & Liu, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1629620 · Cited by 30
Comprehensive Analysis of the Immune Infiltrates of Pyroptosis in Kidney Renal Clear Cell Carcinoma
Sun, Z., Jing, C., Guo, X., Zhang, M., Kong, F., Wang, Z., Jiang, S., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716854 · Cited by 30
Wang, D., Fu, Z., Gao, L., Zeng, J., Xiang, Y., Zhou, L., Tong, X., Wang, X., & Lu, J. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.01.024 · Cited by 30
Regulation of Pyroptosis by ncRNA: A Novel Research Direction
Gao, L., Jiang, Z., Han, Y., Li, Y., & Xiang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.840576 · Cited by 30
“Recent studies have shown that pyroptosis can participate in the process of various diseases, including tumors (Erkes et al., 2020; Zheng and Li, 2020), cardiovascular diseases (Zhaolin et al.”
BackgroundRaptinal Induces Gasdermin E–Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma
Vernon, M., Wilski, N. A., Kotas, D., Cai, W., Pomante, D., Tiago, M., Alnemri, E. S., & Aplin, A. E. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0040 · Cited by 30
Self-citationNoncoding RNA-mediated regulation of pyroptotic cell death in cancer
Wang, M., Zhang, Y., Chang, W., Zhang, L., Syrigos, K. N., & Li, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015587 · Cited by 30
Ren, J., Tao, Y., Peng, M., Xiao, Q., Jing, Y., Huang, J., Yang, J., Lin, C., Sun, M., Li, L., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05357-9 · Cited by 30
“[54] demonstrated that mutant BRAF and MEK inhibitorinduced pyroptosis promoted T cell proliferation and contributed to the antitumor effects in melanoma.”
BackgroundGasdermins: a dual role in pyroptosis and tumor immunity
Yang, J., & Jiang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1322468 · Cited by 30
“In co-administration of B-Raf proto-oncogene (BRAF) and mitogen-activated protein kinase (MEK) inhibitors ampli fi es GSDME-related pyroptosis, leading to the release of HMGB1 (23, 87, 88).”
BackgroundSun, S., Qian, S., Wang, R., Zhao, M., Li, R., Gu, W., Zhao, M., Qian, C., Liu, L., Tang, X., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado0020 · Cited by 30
Chu, L., Yi, Q., Yan, Y., Peng, J., Li, Z., Jiang, F., He, Q., Ouyang, L., Wu, S., Fu, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.882763 · Cited by 29
“Furthermore, combinations of BRAF inhibitors and MEK inhibitors in BRAF mutant melanoma promoted cleavage of GSDME and regulated the tumor immune microenvironment via pyroptosis (11).”
BackgroundHarnessing Pyroptosis for Cancer Immunotherapy
Bourne, C. M., & Taabazuing, C. Y. (2024) · Cells · doi:10.3390/cells13040346 · Cited by 30
“However, resistance can be overcome by using alternative chemotherapeutics such as etoposide to activate caspase-3 to cleave GSDME and induce pyroptosis [67].”
BackgroundInfluentialCai, W., Nguyen, M. Q., Wilski, N. A., Purwin, T. J., Vernon, M., Tiago, M., & Aplin, A. E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3217 · Cited by 28
Self-citationGasdermin E-mediated programmed cell death: An unpaved path to tumor suppression
Wang, Y., Peng, J., Xie, X., Zhang, Z., Li, M., & Yang, M. W. (2021) · Journal of Cancer · doi:10.7150/jca.48989 · Cited by 27
“Moreover, regrowth of residual disease after removing BRAFi + MEKi was sooner and lager in GSDME-KO tumors than control group [63].”
BackgroundInfluentialProctor, M. A., Cruz, J. L. G., Daignault, S. M., Veitch, M., Zeng, B., Ehmann, A., Sabdia, M. B., Snell, C. E., Keane, C., Dolcetti, R., et al. (2021) · Cancers · doi:10.3390/cancers13153733 · Cited by 27
“In 50% of patients with mutant BRAF, BRAF/MEK inhibitors can modify the tumour immune microenvironment to enhance ICI efficacy [3].”
BackgroundBRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it
Tsamis, I., Gomatou, G., Chachali, S.-P., Trontzas, I. P., Patriarcheas, V., Panagiotou, Ε., & Kotteas, E. A. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02849-0 · Cited by 27
“The restoration of cancer cells’ pyroptotic death—potentially with the use of chemotherapeutic drugs— could enhance anti-tumor immunity [89, 90].”
BackgroundLiu, Y.-G., Jiang, S., Zhang, L., Zheng, H., Zhang, T., Zhang, J., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · European journal of medical research · doi:10.1186/s40001-023-01195-3 · Cited by 27
“Other studies including those focusing on the function of intestinal flora in shaping TIME [35] and how to regulate the pyroptosis process in TIME [89] provided different angles in developing new treatment strategies.”
BackgroundSOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death
Rosenbaum, S. R., Caksa, S., Stefanski, C. D., Trachtenberg, I. V., Wilson, H. P., Wilski, N. A., Ott, C. A., Purwin, T. J., Haj, J. I., Pomante, D., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0290 · Cited by 27
Self-citationPyroptosis in glioma: Current management and future application
Guo, Z., Su, Z., Wei, Y., Zhang, X., & Hong, X. (2023) · Immunological Reviews · doi:10.1111/imr.13294 · Cited by 28
“82 In another study, HMGB1 was also found to be a pyroptosis regulator, transforming neuroblastoma apoptosis into pyroptosis through ROS/ ERK1/2/caspase-3/GSDME pathway.”
BackgroundSmall, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma
Wei, J., Xia, Y., Meng, F., Ni, D., Qiu, X., & Zhong, Z. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c01103 · Cited by 27
Identification and Validation of a Pyroptosis-Related Prognostic Model for Gastric Cancer
Liang, C., Fan, J., Liang, C., & Guo, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.699503 · Cited by 27
Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment
Zhang, Y., Yi, S., & Luan, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1519119 · Cited by 26
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Peiffer, L., Farahpour, F., Sriram, A., Spassova, I., Hoffmann, D. E., Kubat, L., Stoitzner, P., Gambichler, T., Sucker, A., Ugurel, S., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02804-4 · Cited by 26
Lelliott, E. J., Mangiola, S., Ramsbottom, K. M., Zethoven, M., Lim, L. R. J., Lau, P. K. H., Oliver, A. J., Martelotto, L. G., Kirby, L., Martin, C., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0401 · Cited by 26
“1 tumors were treated with vehicle, BRAFiþMEKi, CDK4/6i, or triple therapy for 7 days, after which the tumors were harvested and the immune compartment analyzed by flow cytometry.”
BackgroundResultInfluentialThe implication of pyroptosis in cancer immunology: Current advances and prospects
Liu, W., Peng, J., Xiao, M., Cai, Y., Peng, B., Zhang, W.-Q., Li, J., Kang, F., Hong, Q., Liang, Q., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.04.019 · Cited by 26
“Moreover, pyroptosis-mediated chemotherapy exerted a significant effect and provided new ideas for future treatments of melanoma.(16) A recent study has shown that GSDME expression levels have a significant advantage in predicting immune cell infiltration of hepatocellular carcinoma (HCC) and lung adenocarcinoma (LUAD…”
BackgroundZhang, Q., Liu, Y., Fei, Y., Xie, J., Zhao, X., Zhong, Z., & Deng, C. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00482 · Cited by 26
Mechanisms involved in the HMGB1 modulation of tumor multidrug resistance (Review)
Shao, L., Li, Z., Wang, M., Ning, Y., Chen, F.-Q., Gao, X.-Q., Yang, C.-T., Wang, H., & Liu, X. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5272 · Cited by 26
“The release of HMGB1 and GSDME cleavage were inhibited in melanoma BRAFi + MEKi‑resistant cells, and targeting this PCD pathway is a potential strategy for salvage therapy in patients with BRAFi + MEKi‑resistant melanoma (136).”
Nanomaterials evoke pyroptosis boosting cancer immunotherapy
Li, Z., Xi, Z., Fan, C., Xi, X., Zhou, Y., Zhao, M., & Xu, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.011 · Cited by 25
“In some cases, pyroptosis releases HMGB1 to promote tumor cell survival 49,50 .”
New prospects of cancer therapy based on pyroptosis and pyroptosis inducers
Chen, Q., Sun, Y., Wang, S., & Xu, J. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01906-5 · Cited by 25
“Nanocarriers including liposomes [146], hydrogels [147, 148], polymer micelles [149], metal-organic frameworks (MOF) [ 150], and cell membrane biomimetic nanocarriers [151] are commonly used to induce tumor pyroptosis.”
Inhibiting apoptosis and GSDME-mediated pyroptosis attenuates hepatic injury in septic mice
Lu, N., Qin, H., Meng, Z., Yu, Y., Gao, Q. F., Cheng, Z., Liu, C., & Hu, J. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.109923 · Cited by 25
Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
Liu, M., Liu, Q., Hu, K., Dong, Y., Sun, X., Zou, Z., Ji, D., Liu, T., & Yu, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104497 · Cited by 25
Nanomaterials Enhance Pyroptosis-Based Tumor Immunotherapy
Ji, F., Shi, C., Shu, Z., & Li, Z. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s457309 · Cited by 24
“49 In another study, BI2536, a PLK1 kinase inhibitor, increased the chemosensitivity of the tumor to DDP by promoting the conversion of apoptosis to pyroptosis in esophageal squamous cell carcinoma.”
BackgroundThe Therapeutic Potential of Pyroptosis in Melanoma
Zaffaroni, N., & Beretta, G. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021285 · Cited by 24
“The analysis predicted greater sensitivity to paclitaxel, sorafenib and PD0325901, and lesser sensitivity to cisplatin and docetaxel for low-risk patients compared to high-risk patients.”
BackgroundInfluentialImpact of HMGB1 on cancer development and therapeutic insights focused on CNS malignancy
Patra, S., Roy, P., Dey, A., & Mandal, M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189105 · Cited by 24
Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis
Ye, F., Zhang, W., Fan, C., Dong, J., Peng, M., Deng, W., Zhang, H., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04481-0 · Cited by 24
“Recent studies have shown that caspase-3 activation induced by chemotherapy or molecularly targeted drugs induces pyroptosis via specific cleavage of GSDME, resulting in growth inhibition [23, 42, 43].”
BackgroundYang, Y., Wang, S., Wang, X.-X., Guo, S., Wang, H., Shi, Q., Tian, Y., Wang, H., Zhao, T., Zhang, H., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01470-8 · Cited by 22
“To be specific, mutant BRAF and MEK in melanoma cells regulate the infiltration and function of T cells and dendritic cells in TME via GSDME-dependent pyroptosis and HMGB1 secretion [7].”
BackgroundTumor Cell Resistance to the Inhibition of BRAF and MEK1/2
Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 23
“For example, dual BRAF/MEK inhibition induces cleavage of pyroptosis marker gasdermin E (GSDME) and intra-tumoral T cell infiltration, but BRAFi/MEKi resistance attenuates these responses in melanoma [48].”
Li, J., Anraku, Y., & Kataoka, K. (2020) · Angewandte Chemie · doi:10.1002/ange.202004180 · Cited by 22
Oztosun, G., Armstrong, A. E., & Hirbe, A. C. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2558656 · Cited by 21
“MEK inhibitors have been shown to influence apoptosis through various mechanisms; they also induce pyroptosis, which modulates the tumor immune micro-environment and enhances anti-tumor immunity [44].”
CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance
Shi, Z., Tu, J., Ying, Y., Diao, Y., Zhang, P., Liao, S., Xiong, Z., & Huang, S. (2022) · Cancers · doi:10.3390/cancers14174251 · Cited by 21
“Accumulating studies demonstrate that a BRAF inhibitor (BRAFi) can significantly improve the survival of cancer patients with BRAF mutations [56,57].”
BackgroundHou, J., Li, T., Hsu, J.-M., Zhang, X., & Hung, M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101833 · Cited by 21
Yan, Q., Fang, X., Liu, X., Guo, S., Chen, S., Luo, M., Lan, P., & Guan, X. (2023) · Advanced Science · doi:10.1002/advs.202305653 · Cited by 22
Chen, W., He, Y., Zhou, G., Chen, X., Ye, Y., Zhang, G., & Liu, H. (2024) · BMC Medicine · doi:10.1186/s12916-023-03175-0 · Cited by 21
“Pyroptosis has received extensive attention because of its great potential in cancer treatment [14], and there are at least 6 relevant clinical trials in progress [100].”
BackgroundLiu, R.-J., Yu, X.-D., Yan, S.-S., Guo, Z., Zao, X., & Zhang, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5651 · Cited by 21
“For example, GSDME can be cleaved by small molecule kinase inhibitors or following the chemotherapy‑induced activation of caspase‑3, resulting in pyroptosis and the improvement of lung cancer and melanoma treatments (87,94).”
BackgroundTamura, Y., Morikawa, M., Tanabe, R., Miyazono, K., & Koinuma, D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12890 · Cited by 21
Jia, C., Zhang, Z., Tang, J., Cai, M., Zang, J., Shi, K., Sun, Y., Wu, J., Shi, H., Shi, W., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.781365 · Cited by 21
“Indeed, recent evidence has indicated that GSDME promotes lymphocyte infiltration and activation spontaneously or upon targeted inhibitors (Erkes et al., 2020; Wang et al., 2020; Zhang et al., 2020).”
BackgroundIdentification of immune-related cells and genes in the breast invasive carcinoma microenvironment
Chen, X., Wang, Y., Li, Y., Liu, G., Liao, K., & Song, F. (2022) · Aging · doi:10.18632/aging.203879 · Cited by 21
Thompson, E. L., Hu, J., & Niedernhofer, L. J. (2021) · Cancers · doi:10.3390/cancers13092241 · Cited by 20
“However, excretion of HMGB1 is also associated with a proinflammatory and anti-tumor response through activation of dendritic cells and induction of T-cell activation after BRAFi and MEKi treatment [80].”
Background
Metadata
- Authors
- Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Alnemri, Emad S.
- Aplin, Andrew E.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-02-01
- Volume
- 10
- Issue
- 2
- Pages
- 254-269
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7007378
- OpenAlex
- W2993434511
- Cited by
- 459
- References
- 67
- Citations by year
- 2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
- Dr. Ralph and Marian Falk Medical Research Trust (N/A)
- HHS | National Institutes of Health (AR055398, AR074564)
- U.S. Department of Defense (PC150650)
- American Cancer Society (PF-18-096-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
- MeSH terms
- Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.